Compare ZSTK & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZSTK | ALLR |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | Canada | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 21.5M |
| IPO Year | 2023 | 2021 |
| Metric | ZSTK | ALLR |
|---|---|---|
| Price | $5.53 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 16.0K | ★ 64.6K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,676,000.00 | $320,000.00 |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $0.77 |
| 52 Week High | $11.00 | $2.35 |
| Indicator | ZSTK | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 82.33 | 62.51 |
| Support Level | $4.76 | $1.21 |
| Resistance Level | $9.65 | $1.55 |
| Average True Range (ATR) | 0.96 | 0.10 |
| MACD | 0.34 | 0.01 |
| Stochastic Oscillator | 37.28 | 72.22 |
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide Commercial and wholesale business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape. The other segment commercial and wholesale (Phatebo and TruHC), which sell pharmaceutical products and mix of products across multiple categories including food and beverage, cannabis accessories and technology, personal care and wellness.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.